<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;ff=20240510180822&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;ff=20240510180822&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 10 May 2024 22:08:23 +0000</lastbuilddate>
<pubDate>Fri, 10 May 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>2024 Hypertrophic Cardiomyopathy Guideline-at-a-Glance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38727648/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 3:S0735-1097(24)06825-6. doi: 10.1016/j.jacc.2024.04.002. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38727648/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38727648</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.002>10.1016/j.jacc.2024.04.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38727648</guid>
<pubDate>Fri, 10 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Megan Coylewright</dc:creator>
<dc:creator>Morgane Cibotti-Sun</dc:creator>
<dc:creator>Mykela M Moore</dc:creator>
<dc:date>2024-05-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2024 Hypertrophic Cardiomyopathy Guideline-at-a-Glance</dc:title>
<dc:identifier>pmid:38727648</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.002</dc:identifier>
</item>
<item>
<title>2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38727647/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>AIM: The "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy" provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 3:S0735-1097(24)00382-6. doi: 10.1016/j.jacc.2024.02.014. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">AIM: The "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy" provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A comprehensive literature search was conducted from September 14, 2022, to November 22, 2022, encompassing studies, reviews, and other evidence on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through May 23, 2023, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">STRUCTURE: Hypertrophic cardiomyopathy remains a common genetic heart disease reported in populations globally. Recommendations from the "2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy" have been updated with new evidence to guide clinicians.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38727647/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38727647</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.014>10.1016/j.jacc.2024.02.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38727647</guid>
<pubDate>Fri, 10 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Writing Committee Members</dc:creator>
<dc:creator>Steve R Ommen</dc:creator>
<dc:creator>Carolyn Y Ho</dc:creator>
<dc:creator>Irfan M Asif</dc:creator>
<dc:creator>Seshadri Balaji</dc:creator>
<dc:creator>Michael A Burke</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Joseph A Dearani</dc:creator>
<dc:creator>Kelly C Epps</dc:creator>
<dc:creator>Lauren Evanovich</dc:creator>
<dc:creator>Victor A Ferrari</dc:creator>
<dc:creator>José A Joglar</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Jeffrey J Kim</dc:creator>
<dc:creator>Michelle M Kittleson</dc:creator>
<dc:creator>Chayakrit Krittanawong</dc:creator>
<dc:creator>Matthew W Martinez</dc:creator>
<dc:creator>Seema Mital</dc:creator>
<dc:creator>Srihari S Naidu</dc:creator>
<dc:creator>Sara Saberi</dc:creator>
<dc:creator>Christopher Semsarian</dc:creator>
<dc:creator>Sabrina Times</dc:creator>
<dc:creator>Cynthia Burstein Waldman</dc:creator>
<dc:date>2024-05-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:38727647</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.014</dc:identifier>
</item>
<item>
<title>Left atrial intramural haematoma mimicking a thrombus traversing the interatrial septum following thrombolytic therapy for pulmonary embolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38727577/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 10:ehae232. doi: 10.1093/eurheartj/ehae232. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38727577/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38727577</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae232>10.1093/eurheartj/ehae232</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38727577</guid>
<pubDate>Fri, 10 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Takumi Osawa</dc:creator>
<dc:creator>Yoshihide Tanabe</dc:creator>
<dc:creator>Hidetaka Nishina</dc:creator>
<dc:date>2024-05-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Left atrial intramural haematoma mimicking a thrombus traversing the interatrial septum following thrombolytic therapy for pulmonary embolism</dc:title>
<dc:identifier>pmid:38727577</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae232</dc:identifier>
</item>
<item>
<title>Spexin Diminishes Atrial Fibrillation Vulnerability by Acting on Galanin Receptor 2</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38726666/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Spexin reduces atrial fibrillation susceptibility by inhibiting CREB phosphorylation and thus downregulating KCNJ2 and SLN transcription by GALR2 receptor. The spexin/GALR2/CREB signaling pathway represents a novel therapeutic avenue in the development of agents against atrial fibrillation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 10. doi: 10.1161/CIRCULATIONAHA.123.067517. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: G protein-coupled receptors play a critical role in atrial fibrillation (AF). Spexin is a novel ligand of galanin receptors (GALRs). In this study, we investigated the regulation of spexin and GALRs on AF and the underlying mechanisms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Global spexin knockout (SPX-KO) and cardiomyocyte-specific GALRs knockout (GALR-cKO) mice underwent burst pacing electrical stimulation. Optical mapping was used to determine atrial conduction velocity and action potential duration. Atrial myocyte action potential duration and inward rectifying K<sup>+</sup> current (<i>I</i><sub>K1</sub>) were recorded using whole-cell patch clamps. Isolated cardiomyocytes were stained with Fluo-3/AM dye, and intracellular Ca<sup>2+</sup> handling was examined by CCD camera. A mouse model of AF was established by Ang-II (angiotensin II) infusion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Spexin plasma levels in patients with AF were lower than those in subjects without AF, and knockout of spexin increased AF susceptibility in mice. In the atrium of SPX-KO mice, potassium inwardly rectifying channel subfamily J member 2 (KCNJ2) and sarcolipin (SLN) were upregulated; meanwhile, <i>I</i><sub>K1</sub> current was increased and Ca<sup>2+</sup> handling was impaired in isolated atrial myocytes of SPX-KO mice. GALR2-cKO mice, but not GALR1-cKO and GALR3-cKO mice, had a higher incidence of AF, which was associated with higher <i>I</i><sub>K1</sub> current and intracellular Ca<sup>2+</sup> overload. The phosphorylation level of CREB (cyclic AMP responsive element binding protein 1) was upregulated in atrial tissues of SPX-KO and GALR2-cKO mice. Chromatin immunoprecipitation confirmed the recruitment of p-CREB to the proximal promoter regions of KCNJ2 and SLN. Finally, spexin treatment suppressed CREB signaling, decreased <i>I</i><sub>K1</sub> current and intracellular Ca<sup>2+</sup> overload, which thus reduced the inducibility of AF in Ang-II-infused mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Spexin reduces atrial fibrillation susceptibility by inhibiting CREB phosphorylation and thus downregulating KCNJ2 and SLN transcription by GALR2 receptor. The spexin/GALR2/CREB signaling pathway represents a novel therapeutic avenue in the development of agents against atrial fibrillation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38726666/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38726666</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067517>10.1161/CIRCULATIONAHA.123.067517</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38726666</guid>
<pubDate>Fri, 10 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Desheng Li</dc:creator>
<dc:creator>Yang Liu</dc:creator>
<dc:creator>Changzhu Li</dc:creator>
<dc:creator>Zhiwen Zhou</dc:creator>
<dc:creator>Kangyi Gao</dc:creator>
<dc:creator>Hairong Ba</dc:creator>
<dc:creator>Jiming Yang</dc:creator>
<dc:creator>Genlong Xue</dc:creator>
<dc:creator>Dechun Yin</dc:creator>
<dc:creator>Xinbo Zhao</dc:creator>
<dc:creator>Kewei Shen</dc:creator>
<dc:creator>Lingmin Zhang</dc:creator>
<dc:creator>Jialiang Li</dc:creator>
<dc:creator>Chenhong Li</dc:creator>
<dc:creator>Jiahui Song</dc:creator>
<dc:creator>Lexin Zhao</dc:creator>
<dc:creator>Yao Pei</dc:creator>
<dc:creator>Lina Xuan</dc:creator>
<dc:creator>Yang Zhang</dc:creator>
<dc:creator>Yanjie Lu</dc:creator>
<dc:creator>Zhi-Ren Zhang</dc:creator>
<dc:creator>Baofeng Yang</dc:creator>
<dc:creator>Yue Li</dc:creator>
<dc:creator>Zhenwei Pan</dc:creator>
<dc:date>2024-05-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Spexin Diminishes Atrial Fibrillation Vulnerability by Acting on Galanin Receptor 2</dc:title>
<dc:identifier>pmid:38726666</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067517</dc:identifier>
</item>
<item>
<title>Deep mutational scanning of hepatitis B virus reveals a mechanism for cis-preferential reverse transcription</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38723628/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>Hepatitis B virus (HBV) is a small double-stranded DNA virus that chronically infects 296 million people. Over half of its compact genome encodes proteins in two overlapping reading frames, and during evolution, multiple selective pressures can act on shared nucleotides. This study combines an RNA-based HBV cell culture system with deep mutational scanning (DMS) to uncouple cis- and trans-acting sequence requirements in the HBV genome. The results support a leaky ribosome scanning model for...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 2:S0092-8674(24)00403-3. doi: 10.1016/j.cell.2024.04.008. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Hepatitis B virus (HBV) is a small double-stranded DNA virus that chronically infects 296 million people. Over half of its compact genome encodes proteins in two overlapping reading frames, and during evolution, multiple selective pressures can act on shared nucleotides. This study combines an RNA-based HBV cell culture system with deep mutational scanning (DMS) to uncouple cis- and trans-acting sequence requirements in the HBV genome. The results support a leaky ribosome scanning model for polymerase translation, provide a fitness map of the HBV polymerase at single-nucleotide resolution, and identify conserved prolines adjacent to the HBV polymerase termination codon that stall ribosomes. Further experiments indicated that stalled ribosomes tether the nascent polymerase to its template RNA, ensuring cis-preferential RNA packaging and reverse transcription of the HBV genome.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38723628/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38723628</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.008>10.1016/j.cell.2024.04.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38723628</guid>
<pubDate>Thu, 09 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Yingpu Yu</dc:creator>
<dc:creator>Maximilian A Kass</dc:creator>
<dc:creator>Mengyin Zhang</dc:creator>
<dc:creator>Noor Youssef</dc:creator>
<dc:creator>Catherine A Freije</dc:creator>
<dc:creator>Kelly P Brock</dc:creator>
<dc:creator>Lauren C Aguado</dc:creator>
<dc:creator>Leon L Seifert</dc:creator>
<dc:creator>Sanjana Venkittu</dc:creator>
<dc:creator>Xupeng Hong</dc:creator>
<dc:creator>Amir Shlomai</dc:creator>
<dc:creator>Ype P de Jong</dc:creator>
<dc:creator>Debora S Marks</dc:creator>
<dc:creator>Charles M Rice</dc:creator>
<dc:creator>William M Schneider</dc:creator>
<dc:date>2024-05-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Deep mutational scanning of hepatitis B virus reveals a mechanism for cis-preferential reverse transcription</dc:title>
<dc:identifier>pmid:38723628</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.008</dc:identifier>
</item>
<item>
<title>Circadian tumor infiltration and function of CD8&lt;sup>;+&lt;/sup>; T cells dictate immunotherapy efficacy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38723627/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>The quality and quantity of tumor-infiltrating lymphocytes, particularly CD8^(+) T cells, are important parameters for the control of tumor growth and response to immunotherapy. Here, we show in murine and human cancers that these parameters exhibit circadian oscillations, driven by both the endogenous circadian clock of leukocytes and rhythmic leukocyte infiltration, which depends on the circadian clock of endothelial cells in the tumor microenvironment. To harness these rhythms...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 2:S0092-8674(24)00410-0. doi: 10.1016/j.cell.2024.04.015. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The quality and quantity of tumor-infiltrating lymphocytes, particularly CD8<sup>+</sup> T cells, are important parameters for the control of tumor growth and response to immunotherapy. Here, we show in murine and human cancers that these parameters exhibit circadian oscillations, driven by both the endogenous circadian clock of leukocytes and rhythmic leukocyte infiltration, which depends on the circadian clock of endothelial cells in the tumor microenvironment. To harness these rhythms therapeutically, we demonstrate that efficacy of chimeric antigen receptor T cell therapy and immune checkpoint blockade can be improved by adjusting the time of treatment during the day. Furthermore, time-of-day-dependent T cell signatures in murine tumor models predict overall survival in patients with melanoma and correlate with response to anti-PD-1 therapy. Our data demonstrate the functional significance of circadian dynamics in the tumor microenvironment and suggest the importance of leveraging these features for improving future clinical trial design and patient care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38723627/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38723627</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.015>10.1016/j.cell.2024.04.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38723627</guid>
<pubDate>Thu, 09 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Chen Wang</dc:creator>
<dc:creator>Qun Zeng</dc:creator>
<dc:creator>Zeynep Melis Gül</dc:creator>
<dc:creator>Sisi Wang</dc:creator>
<dc:creator>Robert Pick</dc:creator>
<dc:creator>Phil Cheng</dc:creator>
<dc:creator>Ruben Bill</dc:creator>
<dc:creator>Yan Wu</dc:creator>
<dc:creator>Stefan Naulaerts</dc:creator>
<dc:creator>Coline Barnoud</dc:creator>
<dc:creator>Pei-Chun Hsueh</dc:creator>
<dc:creator>Sofie Hedlund Moller</dc:creator>
<dc:creator>Mara Cenerenti</dc:creator>
<dc:creator>Mengzhu Sun</dc:creator>
<dc:creator>Ziyang Su</dc:creator>
<dc:creator>Stéphane Jemelin</dc:creator>
<dc:creator>Volodymyr Petrenko</dc:creator>
<dc:creator>Charna Dibner</dc:creator>
<dc:creator>Stéphanie Hugues</dc:creator>
<dc:creator>Camilla Jandus</dc:creator>
<dc:creator>Zhongwu Li</dc:creator>
<dc:creator>Olivier Michielin</dc:creator>
<dc:creator>Ping-Chih Ho</dc:creator>
<dc:creator>Abhishek D Garg</dc:creator>
<dc:creator>Federico Simonetta</dc:creator>
<dc:creator>Mikaël J Pittet</dc:creator>
<dc:creator>Christoph Scheiermann</dc:creator>
<dc:date>2024-05-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Circadian tumor infiltration and function of CD8&lt;sup>;+&lt;/sup>; T cells dictate immunotherapy efficacy</dc:title>
<dc:identifier>pmid:38723627</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.015</dc:identifier>
</item>
<item>
<title>Circadian-Regulated GR Signaling Mediates Morning Arrhythmias</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38723035/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 May 10;134(10):1327-1329. doi: 10.1161/CIRCRESAHA.124.324571. Epub 2024 May 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38723035/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38723035</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324571>10.1161/CIRCRESAHA.124.324571</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38723035</guid>
<pubDate>Thu, 09 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Inna Rabinovich-Nikitin</dc:creator>
<dc:creator>Molly Crandall</dc:creator>
<dc:creator>Lorrie A Kirshenbaum</dc:creator>
<dc:date>2024-05-09</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Circadian-Regulated GR Signaling Mediates Morning Arrhythmias</dc:title>
<dc:identifier>pmid:38723035</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324571</dc:identifier>
</item>
<item>
<title>Keeps Cardiac Pericytes in Good Shape: Regulator of G-Protein Signaling-5</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38723034/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 May 10;134(10):1256-1258. doi: 10.1161/CIRCRESAHA.124.324476. Epub 2024 May 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38723034/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38723034</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324476>10.1161/CIRCRESAHA.124.324476</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38723034</guid>
<pubDate>Thu, 09 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Michaela Kuhn</dc:creator>
<dc:date>2024-05-09</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Keeps Cardiac Pericytes in Good Shape: Regulator of G-Protein Signaling-5</dc:title>
<dc:identifier>pmid:38723034</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324476</dc:identifier>
</item>
<item>
<title>Pacemaker Channels and the Chronotropic Response in Health and Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38723033/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>Loss or dysregulation of the normally precise control of heart rate via the autonomic nervous system plays a critical role during the development and progression of cardiovascular disease-including ischemic heart disease, heart failure, and arrhythmias. While the clinical significance of regulating changes in heart rate, known as the chronotropic effect, is undeniable, the mechanisms controlling these changes remain not fully understood. Heart rate acceleration and deceleration are mediated by...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 May 10;134(10):1348-1378. doi: 10.1161/CIRCRESAHA.123.323250. Epub 2024 May 9.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Loss or dysregulation of the normally precise control of heart rate via the autonomic nervous system plays a critical role during the development and progression of cardiovascular disease-including ischemic heart disease, heart failure, and arrhythmias. While the clinical significance of regulating changes in heart rate, known as the chronotropic effect, is undeniable, the mechanisms controlling these changes remain not fully understood. Heart rate acceleration and deceleration are mediated by increasing or decreasing the spontaneous firing rate of pacemaker cells in the sinoatrial node. During the transition from rest to activity, sympathetic neurons stimulate these cells by activating β-adrenergic receptors and increasing intracellular cyclic adenosine monophosphate. The same signal transduction pathway is targeted by positive chronotropic drugs such as norepinephrine and dobutamine, which are used in the treatment of cardiogenic shock and severe heart failure. The cyclic adenosine monophosphate-sensitive hyperpolarization-activated current (I<sub>f</sub>) in pacemaker cells is passed by hyperpolarization-activated cyclic nucleotide-gated cation channels and is critical for generating the autonomous heartbeat. In addition, this current has been suggested to play a central role in the chronotropic effect. Recent studies demonstrate that cyclic adenosine monophosphate-dependent regulation of HCN4 (hyperpolarization-activated cyclic nucleotide-gated cation channel isoform 4) acts to stabilize the heart rate, particularly during rapid rate transitions induced by the autonomic nervous system. The mechanism is based on creating a balance between firing and recently discovered nonfiring pacemaker cells in the sinoatrial node. In this way, hyperpolarization-activated cyclic nucleotide-gated cation channels may protect the heart from sinoatrial node dysfunction, secondary arrhythmia of the atria, and potentially fatal tachyarrhythmia of the ventricles. Here, we review the latest findings on sinoatrial node automaticity and discuss the physiological and pathophysiological role of HCN pacemaker channels in the chronotropic response and beyond.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38723033/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38723033</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323250>10.1161/CIRCRESAHA.123.323250</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38723033</guid>
<pubDate>Thu, 09 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Konstantin Hennis</dc:creator>
<dc:creator>Chiara Piantoni</dc:creator>
<dc:creator>Martin Biel</dc:creator>
<dc:creator>Stefanie Fenske</dc:creator>
<dc:creator>Christian Wahl-Schott</dc:creator>
<dc:date>2024-05-09</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Pacemaker Channels and the Chronotropic Response in Health and Disease</dc:title>
<dc:identifier>pmid:38723033</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323250</dc:identifier>
</item>
<item>
<title>Arrhythmogenic Manifestations of Chagas Disease: Perspectives From the Bench to Bedside</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38723031/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>Chagas cardiomyopathy caused by infection with the intracellular parasite Trypanosoma cruzi is the most common and severe expression of human Chagas disease. Heart failure, systemic and pulmonary thromboembolism, arrhythmia, and sudden cardiac death are the principal clinical manifestations of Chagas cardiomyopathy. Ventricular arrhythmias contribute significantly to morbidity and mortality and are the major cause of sudden cardiac death. Significant gaps still exist in the understanding of the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 May 10;134(10):1379-1397. doi: 10.1161/CIRCRESAHA.124.324507. Epub 2024 May 9.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Chagas cardiomyopathy caused by infection with the intracellular parasite <i>Trypanosoma cruzi</i> is the most common and severe expression of human Chagas disease. Heart failure, systemic and pulmonary thromboembolism, arrhythmia, and sudden cardiac death are the principal clinical manifestations of Chagas cardiomyopathy. Ventricular arrhythmias contribute significantly to morbidity and mortality and are the major cause of sudden cardiac death. Significant gaps still exist in the understanding of the pathogenesis mechanisms underlying the arrhythmogenic manifestations of Chagas cardiomyopathy. This article will review the data from experimental studies and translate those findings to draw hypotheses about clinical observations. Human- and animal-based studies at molecular, cellular, tissue, and organ levels suggest 5 main pillars of remodeling caused by the interaction of host and parasite: immunologic, electrical, autonomic, microvascular, and contractile. Integrating these 5 remodeling processes will bring insights into the current knowledge in the field, highlighting some key features for future management of this arrhythmogenic disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38723031/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38723031</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324507>10.1161/CIRCRESAHA.124.324507</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38723031</guid>
<pubDate>Thu, 09 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Danilo Roman-Campos</dc:creator>
<dc:creator>José Antonio Marin-Neto</dc:creator>
<dc:creator>Artur Santos-Miranda</dc:creator>
<dc:creator>Nathan Kong</dc:creator>
<dc:creator>André D'Avila</dc:creator>
<dc:creator>Anis Rassi</dc:creator>
<dc:date>2024-05-09</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Arrhythmogenic Manifestations of Chagas Disease: Perspectives From the Bench to Bedside</dc:title>
<dc:identifier>pmid:38723031</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324507</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38723030/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 May 10;134(10):1232-1233. doi: 10.1161/RES.0000000000000672. Epub 2024 May 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38723030/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38723030</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000672>10.1161/RES.0000000000000672</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38723030</guid>
<pubDate>Thu, 09 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-09</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:38723030</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000672</dc:identifier>
</item>
<item>
<title>Salt Sensitivity of Blood Pressure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38723029/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>The year 2024 marks the centennial of the initiation of the American Heart Association. Over the past 100 years, the American Heart Association has led groundbreaking discoveries in cardiovascular disease including salt sensitivity of blood pressure, which has been studied since the mid-1900s. Salt sensitivity of blood pressure is an important risk factor for cardiovascular events, but the phenotype remains unclear because of insufficient understanding of the underlying mechanisms and lack of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 May 10;134(10):1234-1239. doi: 10.1161/CIRCRESAHA.123.322982. Epub 2024 May 9.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The year 2024 marks the centennial of the initiation of the American Heart Association. Over the past 100 years, the American Heart Association has led groundbreaking discoveries in cardiovascular disease including salt sensitivity of blood pressure, which has been studied since the mid-1900s. Salt sensitivity of blood pressure is an important risk factor for cardiovascular events, but the phenotype remains unclear because of insufficient understanding of the underlying mechanisms and lack of feasible diagnostic tools. In honor of this centennial, we commemorate the initial discovery of salt sensitivity of blood pressure and chronicle the subsequent scientific discoveries and efforts to mitigate salt-induced cardiovascular disease with American Heart Association leading the way. We also highlight determinants of the pathophysiology of salt sensitivity of blood pressure in humans and recent developments in diagnostic methods and future prospects.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38723029/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38723029</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322982>10.1161/CIRCRESAHA.123.322982</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38723029</guid>
<pubDate>Thu, 09 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Jeremiah Afolabi</dc:creator>
<dc:creator>Cheryl L Laffer</dc:creator>
<dc:creator>Heather K Beasley</dc:creator>
<dc:creator>Antentor Hinton</dc:creator>
<dc:creator>Sepiso K Masenga</dc:creator>
<dc:creator>Annet Kirabo</dc:creator>
<dc:date>2024-05-09</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Salt Sensitivity of Blood Pressure</dc:title>
<dc:identifier>pmid:38723029</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322982</dc:identifier>
</item>
<item>
<title>Correction to: Implantable loop recorders in patients with Brugada syndrome: the BruLoop study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38722639/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 9:ehae273. doi: 10.1093/eurheartj/ehae273. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38722639/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38722639</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae273>10.1093/eurheartj/ehae273</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38722639</guid>
<pubDate>Thu, 09 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Implantable loop recorders in patients with Brugada syndrome: the BruLoop study</dc:title>
<dc:identifier>pmid:38722639</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae273</dc:identifier>
</item>
<item>
<title>Anticoagulation for Atrial Fibrillation in Patients With Surgically Occluded Left Atrial Appendage</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38719372/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 14;83(19):1936-1938. doi: 10.1016/j.jacc.2024.03.376.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38719372/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38719372</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.376>10.1016/j.jacc.2024.03.376</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38719372</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Tarun Chakravarty</dc:creator>
<dc:creator>Aum Solanki</dc:creator>
<dc:creator>Neel Bhardwaj</dc:creator>
<dc:creator>Vivek Patel</dc:creator>
<dc:creator>Joanna Chikwe</dc:creator>
<dc:creator>Raj R Makkar</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Anticoagulation for Atrial Fibrillation in Patients With Surgically Occluded Left Atrial Appendage</dc:title>
<dc:identifier>pmid:38719372</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.376</dc:identifier>
</item>
<item>
<title>Postmyocardial Infarction Ventricular Aneurysm: JACC Focus Seminar 5/5</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38719371/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>Ventricular aneurysm represents a rare complication of transmural acute myocardial infarction, although other cardiac, congenital, or metabolic diseases may also predispose to such condition. Ventricular expansion includes all the cardiac layers, usually with a large segment involved. Adverse events include recurrent angina, reduced ventricular stroke volume with congestive heart failure, mitral regurgitation, thromboembolism, and ventricular arrhythmias. Multimodality imaging is paramount to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 14;83(19):1917-1935. doi: 10.1016/j.jacc.2024.02.044.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ventricular aneurysm represents a rare complication of transmural acute myocardial infarction, although other cardiac, congenital, or metabolic diseases may also predispose to such condition. Ventricular expansion includes all the cardiac layers, usually with a large segment involved. Adverse events include recurrent angina, reduced ventricular stroke volume with congestive heart failure, mitral regurgitation, thromboembolism, and ventricular arrhythmias. Multimodality imaging is paramount to provide comprehensive assessment, allowing for appropriate therapeutic decision-making. When indicated, surgical intervention remains the gold standard, although additional therapy (heart failure, anticoagulation, and advanced antiarrhythmic treatment) might be required. However, the STICH (Surgical Treatment for Ischemic Heart Failure) trial did not show any advantage from adding surgical ventricular reconstruction to coronary artery bypass surgery in terms of survival, rehospitalization or symptoms, compared with revascularization alone. Finally, implantable cardiac defibrillator may reduce the risk of fatal arrhythmias.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38719371/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38719371</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.044>10.1016/j.jacc.2024.02.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38719371</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Roberto Lorusso</dc:creator>
<dc:creator>Matteo Matteucci</dc:creator>
<dc:creator>Stamatios Lerakis</dc:creator>
<dc:creator>Daniele Ronco</dc:creator>
<dc:creator>Lorenzo Menicanti</dc:creator>
<dc:creator>Samin K Sharma</dc:creator>
<dc:creator>Pedro R Moreno</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Postmyocardial Infarction Ventricular Aneurysm: JACC Focus Seminar 5/5</dc:title>
<dc:identifier>pmid:38719371</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.044</dc:identifier>
</item>
<item>
<title>Ventricular Pseudoaneurysm and Free Wall Rupture After Acute Myocardial Infarction: JACC Focus Seminar 4/5</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38719370/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>Postinfarction ventricular free-wall rupture is a rare mechanical complication, accounting for &lt;0.01% to 0.02% of cases. As an often-catastrophic event, death typically ensues within minutes due to sudden massive hemopericardium resulting in cardiac tamponade. Early recognition is pivotal, and may allow for pericardial drainage and open surgical repair as the only emergent life-saving procedure. In cases of contained rupture with pseudo-aneurysm (PSA) formation, hospitalization with subsequent...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 14;83(19):1902-1916. doi: 10.1016/j.jacc.2023.10.054.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Postinfarction ventricular free-wall rupture is a rare mechanical complication, accounting for &lt;0.01% to 0.02% of cases. As an often-catastrophic event, death typically ensues within minutes due to sudden massive hemopericardium resulting in cardiac tamponade. Early recognition is pivotal, and may allow for pericardial drainage and open surgical repair as the only emergent life-saving procedure. In cases of contained rupture with pseudo-aneurysm (PSA) formation, hospitalization with subsequent early surgical intervention is warranted. Not uncommonly, PSA may go unrecognized in asymptomatic patients and diagnosed late during subsequent cardiac imaging. In these patients, the unsettling risk of complete rupture demands early surgical repair. Novel developments, in the field of transcatheter-based therapies and multimodality imaging, have enabled percutaneous PSA repair as a feasible alternate strategy for patients at high or prohibitive surgical risk. Contemporary advancements in the diagnosis and treatment of postmyocardial infarction ventricular free-wall rupture and PSA are provided in this review.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38719370/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38719370</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.054>10.1016/j.jacc.2023.10.054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38719370</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Roberto Lorusso</dc:creator>
<dc:creator>Roberto J Cubeddu</dc:creator>
<dc:creator>Matteo Matteucci</dc:creator>
<dc:creator>Daniele Ronco</dc:creator>
<dc:creator>Pedro R Moreno</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ventricular Pseudoaneurysm and Free Wall Rupture After Acute Myocardial Infarction: JACC Focus Seminar 4/5</dc:title>
<dc:identifier>pmid:38719370</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.054</dc:identifier>
</item>
<item>
<title>Ventricular Septal Rupture After Myocardial Infarction: JACC Focus Seminar 3/5</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38719369/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>Ventricular septal rupture remains a dreadful complication of acute myocardial infarction. Although less commonly observed than during the prethrombolytic era, the condition remains complex and is often associated with refractory cardiogenic shock and death. Corrective surgery, although superior to medical treatment, has been associated with high perioperative morbidity and mortality. Transcatheter closure techniques are less invasive to surgery and offer a valuable alternative, particularly in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 14;83(19):1886-1901. doi: 10.1016/j.jacc.2024.01.041.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ventricular septal rupture remains a dreadful complication of acute myocardial infarction. Although less commonly observed than during the prethrombolytic era, the condition remains complex and is often associated with refractory cardiogenic shock and death. Corrective surgery, although superior to medical treatment, has been associated with high perioperative morbidity and mortality. Transcatheter closure techniques are less invasive to surgery and offer a valuable alternative, particularly in patients with cardiogenic shock. In these patients, percutaneous mechanical circulatory support represents a novel opportunity for immediate stabilization and preserved end-organ function. Multimodality imaging can identify favorable septal anatomy for the most appropriate type of repair. The heart team approach will define optimal timing for surgery vs percutaneous repair. Emerging concepts are proposed for a deferred treatment approach, including orthotropic heart transplantation in ideal candidates. Finally, for futile situations, palliative care experts and a medical ethics team will provide the best options for end-of-life clinical decision making.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38719369/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38719369</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.041>10.1016/j.jacc.2024.01.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38719369</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Roberto J Cubeddu</dc:creator>
<dc:creator>Roberto Lorusso</dc:creator>
<dc:creator>Daniele Ronco</dc:creator>
<dc:creator>Matteo Matteucci</dc:creator>
<dc:creator>Michael S Axline</dc:creator>
<dc:creator>Pedro R Moreno</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ventricular Septal Rupture After Myocardial Infarction: JACC Focus Seminar 3/5</dc:title>
<dc:identifier>pmid:38719369</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.041</dc:identifier>
</item>
<item>
<title>Long-Term Cardiovascular Risks of Psychostimulant Drugs for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38719368/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 14;83(19):1883-1885. doi: 10.1016/j.jacc.2024.03.409.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38719368/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38719368</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.409>10.1016/j.jacc.2024.03.409</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38719368</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>G Caleb Alexander</dc:creator>
<dc:creator>Thomas J Moore</dc:creator>
<dc:creator>Eric P Brass</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Long-Term Cardiovascular Risks of Psychostimulant Drugs for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)</dc:title>
<dc:identifier>pmid:38719368</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.409</dc:identifier>
</item>
<item>
<title>Long-Term Cardiovascular Risk Associated With Treatment of Attention-Deficit/Hyperactivity Disorder in Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38719367/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Possible associations between elevated long-term cardiovascular risk and increasing dosage of ADHD treatment use in a young patient group should warrant further investigation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 14;83(19):1870-1882. doi: 10.1016/j.jacc.2024.03.375.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Incrementing numbers of patients treated for attention-deficit/hyperactivity disorder (ADHD) call for scrutiny concerning long-term drug-safety.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aims to investigate associations between long-term use of ADHD treatment and cardiovascular outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using nationwide registers, adult patients first-time initiated on ADHD treatment between 1998 and 2020 were identified. Exposure groups were prior users, &lt;1 defined daily dose (DDD) per day, ≥1 DDD per day determined at start of follow-up, and 1 year after patients' first claimed prescription. Outcomes were acute coronary syndromes, stroke, heart failure, and a composite of the above.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At start of follow-up, 26,357, 31,211, and 15,696 individuals were correspondingly categorized as prior users (42% female, median age: 30 years [Q1-Q3: 23-41 years]), &lt;1 DDD per day (47% female, median age: 31 years [Q1-Q3: 24-41 years]), and ≥1 DDD per day (47% female, median age: 33 years [Q1-Q3: 25-41 years]), respectively. Comparing ≥1 DDD per day with prior users, elevated standardized 10-year absolute risk of stroke (2.1% [95% CI: 1.8%-2.4%] vs 1.7% [95% CI: 1.5%-1.9%]), heart failure (1.2% [95% CI: 0.9%-1.4%] vs 0.7% [95% CI: 0.6%-0.8%]), and the composite outcome (3.9% [95% CI: 3.4%-4.3%] vs 3.0% [95% CI: 2.8 %-3.2%]) was found-with corresponding risk ratios of 1.2 (95% CI: 1.0-1.5), 1.7 (95% CI: 1.3-2.2), and 1.3 (95% CI: 1.1-1.5). No apparent associations were found for acute coronary syndrome (1.0% [95% CI: 0.8%-1.2%] vs 0.9% [95% CI: 0.8%-1.0%]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Possible associations between elevated long-term cardiovascular risk and increasing dosage of ADHD treatment use in a young patient group should warrant further investigation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38719367/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38719367</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.375>10.1016/j.jacc.2024.03.375</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38719367</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Anders Holt</dc:creator>
<dc:creator>Jarl E Strange</dc:creator>
<dc:creator>Peter Vibe Rasmussen</dc:creator>
<dc:creator>Nina Nouhravesh</dc:creator>
<dc:creator>Sebastian Kinnberg Nielsen</dc:creator>
<dc:creator>Caroline Sindet-Pedersen</dc:creator>
<dc:creator>Emil Loldrup Fosbøl</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Christian Torp-Pedersen</dc:creator>
<dc:creator>Gunnar H Gislason</dc:creator>
<dc:creator>Patricia McGettigan</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Morten Lamberts</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Long-Term Cardiovascular Risk Associated With Treatment of Attention-Deficit/Hyperactivity Disorder in Adults</dc:title>
<dc:identifier>pmid:38719367</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.375</dc:identifier>
</item>
<item>
<title>Predictors of Arrhythmic Outcomes in Patients With Dilated and Nondilated Left Ventricular Cardiomyopathies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38719366/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 14;83(19):1852-1854. doi: 10.1016/j.jacc.2024.03.404.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38719366/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38719366</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.404>10.1016/j.jacc.2024.03.404</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38719366</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>John Gorcsan</dc:creator>
<dc:creator>Shunsuke Eguchi</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Predictors of Arrhythmic Outcomes in Patients With Dilated and Nondilated Left Ventricular Cardiomyopathies</dc:title>
<dc:identifier>pmid:38719366</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.404</dc:identifier>
</item>
<item>
<title>Magnetic Resonance Imaging Characterization and Clinical Outcomes of Dilated and Arrhythmogenic Left Ventricular Cardiomyopathies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38719365/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240510180822&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In a multicenter cohort of patients with DCM and NDLVC, septal LGE together with LV dilatation, age, advanced disease, and frequent and repetitive ventricular arrhythmias were powerful predictors of major arrhythmic events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 14;83(19):1841-1851. doi: 10.1016/j.jacc.2024.02.041.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Nondilated left ventricular cardiomyopathy (NDLVC) has been recently differentiated from dilated cardiomyopathy (DCM). A comprehensive characterization of these 2 entities using cardiac magnetic resonance (CMR) and genetic testing has never been performed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to provide a thorough characterization and assess clinical outcomes in a large multicenter cohort of patients with DCM and NDLVC.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 462 patients with DCM (227) or NDLVC (235) with CMR data from 4 different referral centers were retrospectively analyzed. The study endpoint was a composite of sudden cardiac death or major ventricular arrhythmias.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In comparison to DCM, NDLVC had a higher prevalence of pathogenic or likely pathogenic variants of arrhythmogenic genes (40% vs 23%; P &lt; 0.001), higher left ventricular (LV) systolic function (LV ejection fraction: 51% ± 12% vs 36% ± 15%; P &lt; 0.001) and higher prevalence of free-wall late gadolinium enhancement (LGE) (27% vs 14%; P &lt; 0.001). Conversely, DCM showed higher prevalence of pathogenic or likely pathogenic variants of nonarrhythmogenic genes (23% vs 12%; P = 0.002) and septal LGE (45% vs 32%; P = 0.004). Over a median follow-up of 81 months (Q1-Q3: 40-132 months), the study outcome occurred in 98 (21%) patients. LGE with septal location (HR: 1.929; 95% CI: 1.033-3.601; P = 0.039) was independently associated with the risk of sudden cardiac death or major ventricular arrhythmias together with LV dilatation, older age, advanced NYHA functional class, frequent ventricular ectopic activity, and nonsustained ventricular tachycardia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In a multicenter cohort of patients with DCM and NDLVC, septal LGE together with LV dilatation, age, advanced disease, and frequent and repetitive ventricular arrhythmias were powerful predictors of major arrhythmic events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38719365/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240510180822&v=2.18.0.post9+e462414">38719365</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.041>10.1016/j.jacc.2024.02.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38719365</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Matteo Castrichini</dc:creator>
<dc:creator>Antonio De Luca</dc:creator>
<dc:creator>Giulia De Angelis</dc:creator>
<dc:creator>Raquel Neves</dc:creator>
<dc:creator>Alessia Paldino</dc:creator>
<dc:creator>Matteo Dal Ferro</dc:creator>
<dc:creator>Giulia Barbati</dc:creator>
<dc:creator>Kristen Medo</dc:creator>
<dc:creator>Andrea Barison</dc:creator>
<dc:creator>Chrysanthos Grigoratos</dc:creator>
<dc:creator>Marta Gigli</dc:creator>
<dc:creator>Davide Stolfo</dc:creator>
<dc:creator>Francesca Brun</dc:creator>
<dc:creator>Daniel W Groves</dc:creator>
<dc:creator>Robert Quaife</dc:creator>
<dc:creator>Ramone Eldemire</dc:creator>
<dc:creator>Sharon Graw</dc:creator>
<dc:creator>Jeffrey Addison</dc:creator>
<dc:creator>Giancarlo Todiere</dc:creator>
<dc:creator>Ignazio Alessio Gueli</dc:creator>
<dc:creator>Nicoletta Botto</dc:creator>
<dc:creator>Michele Emdin</dc:creator>
<dc:creator>Giovanni Donato Aquaro</dc:creator>
<dc:creator>Ramin Garmany</dc:creator>
<dc:creator>Naveen L Pereira</dc:creator>
<dc:creator>Matthew R G Taylor</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>Gianfranco Sinagra</dc:creator>
<dc:creator>Luisa Mestroni</dc:creator>
<dc:creator>John R Giudicessi</dc:creator>
<dc:creator>Marco Merlo</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Magnetic Resonance Imaging Characterization and Clinical Outcomes of Dilated and Arrhythmogenic Left Ventricular Cardiomyopathies</dc:title>
<dc:identifier>pmid:38719365</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.041</dc:identifier>
</item>





























</channel>
</rss>